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Infectious diseases are a leading cause of death world-wide and there is a growing need for 
new anti-infective agents to combat multi-resistant strains of bacteria and fungi. Marine 
natural products are promising sources of novel antimicrobial compounds. In the present 
thesis, an investigation into the antimicrobial metabolites of Arctic and sub-Arctic marine 
invertebrate species is presented. Extracts of seven ascidian species, six sponge species, a 
soft-alcyonid coral and a bryozoan species, were screened for their antimicrobial activities. 
The extracts were pre-fractionated by solid phase extraction (SPE) and purified by reverse-
phase high-performance liquid chromatography (RP-HPLC). Active metabolites were 
characterized by electrospray ionization mass spectrometry (ESI-MS) and nuclear magnetic 
resonance (NMR) techniques.  
 
The antibacterial tyrosine-derived guanidines, 3-dihydroxy-tubastrine and tubastrine, have 
been isolated from the ascidian Dendrodoa aggregata. This is the first report on the isolation 
of active metabolites from D. aggregata. 3-dihydroxy-tubastrine has previously been isolated 
from the Australian sponge species Spongosorites sp. The compound was present in high 
concentrations in extracts of the ascidian and could serve as a chemotaxonomic marker for the 
species.  
 
Extracts of the ascidian Synoicum pulmonaria displayed the highest antimicrobial activities in 
our assays. Bio-guided fractionation of the extract, revealed the presence of three novel 
compounds, named synoxazolidinones A, B and C. The structures of the compounds were 
elucidated by spectroscopic methods including 1D and 2D NMR techniques, and analysis of 
mass spectrometric data. The absolute configuration of the compounds was also established 
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by computational methods. The synoxazolidinones contain a unique 4-oxazolidinone core 
rarely encountered in natural products. Biogenetically, the compounds appear to be derived 
from arginine and tyrosine. This is the first report on the chemistry of S. pulmonaria. 
Synoxazolidinones also displayed anticancer activities and provide novel chemical scaffolds 
for structure-activity relationship studies which are currently being carried out.  
 
The dibrominated tryptophan-derived metabolite, eusynstyelamide B, and three new 
derivatives, eusynstyelamides D, E and F, have been isolated from the bryozoan Tegella cf. 
spitzbergensis. The structures of the compounds were elucidated by mass spectrometry and, 
1D and 2D NMR techniques.  All four compounds displayed potent antibacterial activities in 
our assays. This is the first report of bioactive metabolites from T. spitzbergensis. 
Eusynstyelamide B has previously been isolated from the Australian ascidian Eusynstyela 
latericius. The presence of the same metabolites in different organisms and environments, 
suggests biosynthesis by symbiotic microorganisms. 
 
In addition, this thesis provides background information on natural product research and 
current antimicrobial investigations of marine invertebrate species. The potential of Arctic 
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1.1 Antibiotics  
 
The emergence and re-emergence of resistant bacteria is one of the major challenges facing 
the pharmaceutical industry today. Even though the extent and speed of emergence of 
bacterial resistance to antimicrobial agents vary with different types of drugs, resistance has 
so far developed to all known antimicrobial drugs1. The prevalence of infectious diseases 
caused by antimicrobial resistant human pathogens is rapidly increasing. This includes the 
worldwide emergence of multidrug-resistant Mycobacterium tuberculosis2 3. Other examples 
of microbial resistance to conventional antibiotics include vancomycin resistance in 
Staphylococcus aureus (VRSA) and enterococci (VRE)4, resistance to beta-lactam antibiotics, 
such as the cephalosporins in the gram-negative bacilli Pseudomonas aeruginosa and 
Escherichia coli5, and penicillin resistance (often multidrug-resistant) in pneumococci6. 
Resistance has also spread to a variety of non-bacterial pathogens, such as viruses, fungi and 
parasites. The development of resistance to antifungal agents by opportunistic fungal 
pathogens such as Candida albicans7 and Saccharomyces cerevisiae8 which can cause life-
threatening systemic infections in immunocompromised individuals such as HIV and cancer 
patients, is on the rise9.  
  
Resistance develops by genetic mutations10 or by the acquisition of exogenous genetic 
material11-14. Chemical modification of known antibiotics has been the most frequently 
employed method to address the problem of resistance. For example derivation of the basic 
nuclear structure of the penicillins, 6-amino-penicillinic acid,  yielded compounds with 
activity against gram-negative bacilli (ampicillin, amoxicillin, carbenicillin, ticarcillin, 
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mezlocillin, azlocillin, piperacillin, and a variety of other “broadspectrum” penicillins), and β-
lactams with activity against β-lactamase producing S. aureus and coagulase negative 
staphylococci (methicillin and a variety of other antistaphylococcal penicillins)15. 
Modifications of the cephalosporin molecule have resulted in  alterations in its in vitro 
spectrum of activity, its resistance to β-lactamases, and its pharmacokinetic properties16. 
Nonetheless, as each new analogue has been introduced over the years, it has ultimately been 
succeeded by the emergence of resistant organisms17. One of the major contributing factors to 
this is the abuse and overuse of new antibiotics. This is a practice that needs to be addressed18. 
The picture is further complicated by the fact that the speed of discovery and development of 
new antimicrobial drugs active against multidrug-resistant organisms have slowed down 
considerably, although billions of dollars are annually invested in this research area19. There 
are several reasons for this apparently contradictory situation, including the even greater costs 
of bringing a new antibiotic from discovery to the market. This is currently estimated at 
between $100 million and $350 million in the United States alone1, 20. Another reason is the 
limited revenue from sales expected by pharmaceutical companies due to the short duration of 
treatment with antibiotics relative to other drugs, such as cholesterol and hypertension agents, 
which are consumed for prolonged periods and relieve symptoms rather than provide a cure21. 
Only two of the few antibiotics introduced in the last 20 years, the oxazolidinones (which 
inhibit bacterial protein synthesis) and cationic peptides (which permeabilize bacterial 
membranes), have unconventional modes of action22. 
 
There is a need to target screening more broadly to ensure that rare activities of unanticipated 
mode-of action are not missed23 and to concentrate on the discovery of novel structural 
scaffolds to minimize the problem of resistance24. 
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1.2 Natural products 
 
Humans have always relied on nature for their supplies of medicine. Plants have been used for 
thousands of years for different remedies in traditional medicine systems of many cultures in 
places such as Africa, the Americas25-27 and Asia28. Records show that the ancient Egyptians 
have been using myrrh for the local treatment of wounds as early as 2500 B.C. and papyri 
dating back to 2000 B.C. record the use of honey for the same purpose29. Records from 
Mesopotamia, written on clay tablets dating from 2600 B.C., describe the use of oils from 
plants such as cedars, cypress and poppy juice for the treatment of coughs, colds, parasitic 
infections and inflammation30. Records from 1100 B.C. show the use of herbal medicine in 
China28 and documentation from about 1000 B.C. describes the Indian Ayurvedic system, 
which formed the basis for Tibetan medicine31. Hippocrates mentioned the wound healing 
properties of myrrh in 400 B.C.29 and writings by the Greek philosopher and natural scientist, 
Theophrastus (~ 300 B.C.) portray how the Greeks dealt with the medicinal qualities of herbs. 
The Arabs preserved much of the Greco-Roman expertise in the Middle Ages in works such 
as Canon Medicinae by the Persian pharmacist, physician, philosopher and poet Avicenna30. 
The modern era of natural products in medicine is regarded to have began with the isolation 
of the first commercial pure natural product, morphine, by E. Merck in 1826 from opium 
produced by seed pods of the poppy, Papaver somniferum32.  
 
Data collected from 1959 to 1980, indicated that 25% of prescribed drugs in the United States 
were derived from plant extracts. Currently, at least 119 chemical substances, derived from 90 
plant species, are important drugs used in many countries33, 34. The discovery of penicillin 
from fungal strains of Penicillium notatum in 192817 started an era of massive screening 
projects of microorganisms. Approximately 80% of drugs are either natural products or 
 9
derivatives of natural products21, including some well known examples such as the antibiotic 
streptomycin from the fungi Streptomyces griseus, the antimalarial artemisinin from the 
wormwood, Artemisia annua,  and taxol from the bark of the yew tree, Taxus brevifolia30. 
 
Between 2005 and 2007, 13 natural product derived drugs were approved in the United States. 
Five of these, the anticancer peptides exanatide and ziconotide, and the small molecules 
ixabepilone (anticancer agent), retapamulin (antibiotic) and trabectedin (anticancer 
compound), represent the first members of new classes of drugs35, 36.  Just in the case of 
polyketides, high-throughput screenings have led to more than 20 commercial drugs with a 
“hit rate” of 0.3% for natural products compared to the <0.001% hit rate of synthetic 
libraries37. 
 
1.2.1 Natural product drugs:  Challenges and prospects 
 
Despite the successful record of natural products in drug discovery, many pharmaceutical 
firms have eliminated their natural product research in the last decade21. Even though more 
than 100 natural product based drugs are currently in clinical trials, this represents a drop of 
about 30% between 2001 and 200835. Companies involved in drug discovery are under 
tremendous pressure to hit the target very quickly and profitably when it comes to new drugs. 
The inherent problems of natural product discovery such as the slow identification process 
due to the often complex nature of natural products with numerous oxygen-containing 
substituents and a number of stereocenters38. Furthermore, reliable access and supply are a 
problem, as well as intellectual property concerns of local authorities39. All these factors lead 
drug companies to prefer screening pure compounds from synthetic libraries21.  
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Seasonal or environmental variations in the chemical composition of living organisms can 
cause problems with initial detection of active compounds and subsequent re-purification and 
repetition of assays. The initial concentration of active metabolites may be too low to be 
effectively detected by high-throughput screenings and assays can be plagued by poor 
solubility, by fluorescent or coloured contaminants or by the key compound being unstable in 
the extract mixture21. Synergistic effects can also occur where activity is lost upon separation 
of the constituents40. Dereplication procedures involving completion of structural 
characterization in order to determine whether the molecule is already known, are often time 
consuming.   
 
A number of strategies are currently in use to address the challenges of drug discovery from 
natural products. One of these is so-called “smart screening”, involving the use of strains of 
microorganisms for antimicrobial testing which are resistant to common antibiotics, thereby 
lowering the chances of rediscovery of known metabolites41. Another strategy is molecular 
target specific screening42, 43. Further evolution in metagenomics is expected to access a 
number of biosynthetic products44. Advances in analytical methods are also being applied to 
high-throughput screenings in order to facilitate dereplication based on various hyphenated 
techniques. Each of these methods have their own advantages or drawbacks in sensitivity, 
resolution, time, sample size and efficiency in searching most of the commercial databases 
(AntiBase45, Dictionary of Natural Products46, MarinLit47 and SciFinder Scholar or CAPlus).  
These techniques include LC/MS48, 49, LC/MS/MS50-52 and various semi-atuomated systems 
involving HPLC/NMR53-55, often with cryo-probe NMR requiring only microgram samples56, 
57. An example of HPLC-NMR is a semi-automated system where substances from HPLC are 
captured by solid-phase-extraction cartridges and eluted into an NMR cryoprobe (HPLC-SPE-
NMR)58. Research is also being carried out into the development of nano-NMR59.  
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Traditionally, soil bacteria (mainly actinomyecetes), fungi and higher plants, have been the 
main sources of natural products22, 60, 61. With estimates of numbers of living species ranging 
from 2-100 million21, where the marine environment comprises approximately half of the total 
global biodiversity62, it is obvious that the natural world represents a great wealth of 
resources. Unique structures are being discovered in organisms living under extreme 
conditions63, 64 such as the great sea depths (piezophiles). One example is abyssomicin, a 
polycyclic antibiotic from an ocean floor sediment bacterium65 and haloduracin, a lanthionine 
containing peptide antibiotic from bacteria living at an extreme pH of >9.0 (alkaliphile)66. The 
diversity of chemistry encountered in bioactive natural products arising from factors such as  
multiple chiral centres, heterocyclic substituents, and polycyclic structures, is by no means 
rivaled by combinatorial libraries67.  Even though most natural product drugs do not comply 
with Lipinski’s Rule-of-Five for orally available compounds due to their higher molecular 
weights, more rotable bonds and more stereogenic centres, they retain relatively low log P 
values and are generally more readily absorbed than synthetic drugs68. In the years to come, 









1.3 The marine environment 
 
Life on earth evolved in the seas billions of years ago and the greatest biodiversity of life is 
found in the oceans69. Out of the 36 phyla of life 34 are represented in the marine 
environment and 21 of these are exclusively marine. The oceans cover more than 70% of the 
earth’s surface and contain more than 300 000 described species of plants and animals70.  It is 
estimated that this is a small percentage of the total number of species71. Marine plants and 
animals have adapted to divers habitats ranging from tropical, shallow-water coral reefs to 
temperate areas and sub-zero, deep-ocean trenches with high-pressure and no light62. These 
vast differences in the ecosystems of the marine environment, have resulted in the production 
of structurally novel, biologically active secondary metabolites unknown from terrestrial 
sources72. The evolution of these metabolites has been driven by various ecological pressures 
including competition for space, biofouling of surfaces, predation and successful reproduction 
over distances70. While rare in terrestrial metabolites, marine natural products are often 
halogenated due to the abundance of bromide and chloride ions in seawater. It is noteworthy 
that bromine is the most commonly found halogen in marine compounds, even though its 
concentration in seawater is lower than that of chlorine73. 
 
Bacteria occur in seawater at concentrations of approximately one million cells per milliliter. 
Marine plants and animals are constantly exposed to high concentrations of bacteria, many of 
which are opportunistically pathogenic and readily attach when provided an appropriate 
surface. Bacteria associated with the surfaces, tissues, and internal spaces of marine 
invertebrates and animals, experience divers microenvironments and therefore have 
tremendous potential as a source of novel secondary metabolites72. 
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1.4 Marine natural products 
 
Little is known of the history of the use of marine sources in traditional medicines, but it has 
been reported that marine algae have been used in Chinese folk medicine for more than two 
thousand years74. Documentation from around 40-90 A.D. shows the use of marine 
invertebrates and fishes for the treatment of various diseases and ailments such as toothaches, 
ulcers and boils by the Greeks75. The ancient Phoenicians employed secretions from mollusks 
to produce purple dyes for cloth and seaweed have long been used as fertilizers76.  Even 
though there are reports from the late 1940’s of bioactivity from marine sources77, the first 
notable discoveries were of the nucleosides spongothymidine in 195078, 79 and spongouridine 
in 195580 from the Caribbean sponge Crypthitheca crypta. The compounds were found to 
possess antiviral activity and synthetic analogue studies led to the development of the 
clinically relevant anticancer agent Ara-C approximately 15 years later81, along with the 
antiviral compound Ara-A30, 76, 82.  
 
Systematic investigation of the marine environment as a source for novel bioactive natural 
products began in earnest in the mid -1970’s76, as improvements in scuba and submersible 
technologies made physical access to the oceans possible69, 82. The field of marine natural 
products is now 40 years old and Blunt et al. report that more than 15 000 marine natural 
products have been isolated in the period from 1965 to 200583. The number of reported 
marine natural products in 2007 was 17 00084 and with reports of 1065 new compounds in 
200885, the number currently could be approaching 20 000. The compounds so far isolated 
from marine invertebrates often have no comparable equivalents in terrestrial sources82. 
 
 14
Apart from the aforementioned Ara-A and Ara-C, only two marine natural product derived 
drugs have successfully reached the market as thereapetic drugs, as of mid 200986. Ziconotide 
(Prialt) is the synthetic equivalent of a peptide first purified in 1984 from the venom of a 
marine mollusk Conus geographus87. The drug was approved in the United States in 2004 and 
in the European Union in 2005 for the management of severe chronic pain 88. Trabectedin 
(Yondelis; ET-743), a tetrahydroisoquinolone alkaloid characterized at the end of the 
1980’s89, is a synthetic antineoplastic agent derived from the Caribbean tunicate Ecteinascidia 
turbinate and is currently used in Europe for treatment of advanced soft tissue sarcoma and 
ovarian cancer90. Approximately 13 other compounds are currently undergoing various stages 
of clinical trials86. The anti-inflammatory pseudopterosins, isolated from the Caribbean 
gorgonian Pseudopterogorgia elisabethae91, 92 are used as constituents of Estee Lauders anti-
wrinkle cream, Resilience, and are a good example of commercialized human use of marine 
natural products82. Considering the short history of marine drug discovery and the odds of a 
natural compound reaching clinical use being estimated at 1 in 4,000-10,00069, coupled with 
the fact that HPLC, one of the essentials of modern isolation methods, was not available until 
the late 1970’s82, it is understandable that the field has evolved slowly. Discovery of 
compounds has been relatively simple, but acquiring the large amounts of sample necessary 
for development, was and still is, a major challenge.  
 
There are several methods which can be applied to ensure adequate supply of a bioactive 
compound from a marine source. These include collection, aquaculture, tissue culture, 
chemical synthesis, symbiont culture and molecular biological approaches69. Ecologically 
sustainable large-scale collection is often difficult to achieve. Aquaculture and cell culture 
have been successfully attempted as in the case of halicondrin B69, 82, an anti-tumour  
macrolide originally isolated from the Japanese sponge Halichondria okadai93, 94. However, it 
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was ultimately total synthesis of the compound95 which led to the development of the drug 
E738982, which is currently in Phase III clinical trials for breast cancer and Phase II trials for 
prostate cancer in the US and EU, as well as Phase II trials in the EU for sarcoma86. Due to 
the structural similarities of many invertebrate compounds to microbial metabolites, it is  
suspected that many of these compounds actually originate from symbiotic microorganisms, 
as in the case of many peptides96. Actual proof of such production was first demonstrated by 
Hamann and co-workers in 2003, when they showed that the manzamines, a family of 
alkaloids originally isolated from an Indonesian sponge Acanthostrongylophora sp. with 
activity against tuberculosis, HIV and AIDS opportunistic fungal infections97, were actually 
produced by the culturable symbiotic microbe Micromonospora sp.98  Many researchers are 
looking at developments in the field of molecular biology for genetic control of biosynthesis, 
either from an invertebrate or its symbiont, thus providing solutions for the supply problem as 
well as yielding novel compounds21, 69, 82. 
 
The list of marine pharmaceuticals currently in clinical trials does not include new 
antibiotics86 and clearly reflects the focus of past funding, which has been on the development 
of new anticancer agents82.  However, many researchers are directing their efforts at 
investigating the marine environment for the presence of potential antibiotics, antimalarial 
agents, anti-tuberculosis drugs and cures for other infective diseases70, 97, 99-101. Recently,  a 
combinatorial library of 3828 compounds based on the core structure of the psammaplins, 
symmetrical bromotyrosine-derived disulfide dimers originally isolated from the 
Psammaplysilla sponge102, 103, resulted in six compounds with activities against methicillin 
and vancomycin resistant strains of S. areus at a minimum inhibitory concentration (MIC) of 
less than 1 μg/ml104.  
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Cold-water marine organisms or psychrophiles are found in waters with temperatures ranging 
from -2 to +4 °C, including the polar deep sea, the temperate and tropical deep-sea where the 
temperature is nearly constant 4 °C, Antarctica, Canadian Maritimes, the Northern Sea of 
Japan and the North Sea above 60 °N latitude84. Diverse and highly bioactive compounds 
have been isolated from these sources including mixirins A-C (cyclic lipopeptides isolated 
from a Bacillus sp. near the North Pole with potent anticancer activity)105. The  structurally 
unique acyclic, dimeric 3-alkyl pyridine alkaloid, viscosaline, was isolated from the Arctic 
sponge Haliclona viscosa106 and has a likely feeding deterrent activity in the organism107. The 
majority of the marine natural products currently being reported originate from warm climates 
such as the Caribbean, the China Sea, the Indian Ocean, Japan and the Western Pacific108. 













1.5 Marine alkaloids  
 
Over 20 structural classes of antibiotics have so far been discovered through natural product 
screening. Among these are the chloramphenicols, tetracyclines, macrolides, polyenes, 
glycopeptides, lincosamides, cycloserines, streptolydigins, coumarins (including novobiocin), 
rifamycins, cephalosporins, glycolipids, polyoxins, phosphonates, elfamycins, cephamycins, 
monobactams, carbapenems, and lipopeptides17. Alkaloids are nitrogen-containing 
compounds and it has been estimated that approximately 40% of all marine natural products 
which have been reported since 1965, contain nitrogen108. Alkaloids also occur in plants, 
microorganisms and animals. These metabolites display significant biological activity and are 
often useful as drugs or biological probes for physiological studies109. A number of marine 
alkaloids have exhibited antimicrobial activity85, 108, 110-112. 
 
1.5.1 Marine bromotyrosine guanidines 
 
A large number of the reported marine tyrosine guanidines, have been brominated 
compounds. Bromotyrosine metabolites have been steadily reported since the end of the 
1960’s. A wide range of bioactivities have been associated with these compounds including 
antimicrobial, antifouling, antiviral and anticancer activities113. Generally, the isolation of 
guanidine alkaloids from complex mixtures is difficult due to their basic nature and high 
polarity114. Examples of bromotryrosine guanidine derivatives isolated from marine 
organisms, presented in Figure 1, include aplysinamisine II, an antimicrobial and cytotoxic 
alkaloid isolated from the sponge Aplysina cauliformis115. An unnamed enzyme inhibitor was 
isolated from the sponge Oceanapia sp116. Ianthelline is an antimicrobial alkaloid isolated 
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from the sponge Ianthella ardis117. Purealidin O is an amidase inhibitor, also isolated from the 
sponge Oceanapia sp118. 
 
  
                         Aplysinamisine II 
 
                      Oceanapia metabolite  
           
                     Ianthelline                                                              Purealidin O 
 
Figure 1. Structures of aplysinamisine II, an Oceanapia metabolite, ianthelline and purealidin O. 
 
1.5.2 Marine bromo-indole guanidines 
 
A number of marine, bromo-indole guanidines, derived from the amino acids tryptophan and 
arginine, have been reported114. These include the cytotoxic N-(6-bromo-1H-indolyl-3-
carbonyl)-L-arginine and N-(6-bromo-1H-indolyl-3-carbonyl)-L-enduracididine (containing 
the rare amino acid enduracididine) (Figure 2), from the ascidian Leptoclinides dubius119. 
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Barettin120, 121 and dihydrobarettin121 (Figure 2), are antifouling agents isolated from the 
sponge Geodia baretti.  
                                         
N-(6-bromo-1H-indolyl-3-carbonyl)-L-arginine                     N-(6-bromo-1H-indolyl-3-carbonyl)-L-                   














                   
                             Barettin                                                                   Dihydrobarettin 
 
Figure 2. Structures of N-(6-bromo-1H-indolyl-3-carbonyl)-L-arginine, N-(6-bromo-1H-indolyl-3-
carbonyl)-L-enduracididine, barettin and dihydrobarettin.  
 
1.5.3 Marine oxazolidinones 
 
Although rare in nature, a few oxazolidinones have nevertheless been reported from marine 
organisms. The most common structural motif is the 2-oxazolidinone configuration of the 
five-membered ring. A dibrominated phenolic derivative containing two 2-oxazolidinone 
groups (LL-PAA216), has been isolated from the sponge Verongia lacunosa collected off the 
coast of Puerto Rico122 (Figure 3). The compound did not exhibit any significant antimicrobial 
activity. A derivative of the Verongia metabolite, with an O-methyl group attached to the 5C 
of one of the oxazolidinone-rings, has been reported from the Caribbean sponge Aplysina 
insularis123 (Figure 3).  
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The antibacterial lipoxazolidinones A, B, and C are in addition to the compounds presented in 
the current study, the only other 4-oxazolidinones reported from nature. The metabolites were 
isolated from a marine actinomycete strain of the genus Marinspora, collected from a Guam 
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2. Antimicrobial natural products from invertebrate species  
2.1 Antimicrobial natural products from sponge species 
 
Sponges are undoubtedly the most widely investigated organisms in marine natural product 
history. Allegedly, a new molecule has been isolated from sponges every two days within the 
last two decades125. All chemical classes are widely represented among the sponges. The vast 
chemodiversity of sponge species is probably due to their position in the Tree of Life, as the 
first examples of multicellular organisms. Sponges emerged approximately 500-550 million 
years ago and are exclusively aquatic. A sponge is a double cell-walled bag pierced with a 
very large number of small holes called ostioles and with an opening called the oscule. The 
cell membrane consists of many combinations of phospholipids and sterols, most of which are 
absent from the cell walls of other animals. The constant movement of the flagellated cells 
lining the inner wall, the chaonocytes, draws water, oxygen and nutrients into the sponge and 
pushes it out through the oscule. Between the outside of the sponge and the interior is the 
mesohyl, which consists of collagen fibres and various types of cells including the 
archaeocytes, which are able to turn into any other type of cell. The mesohyl also contains 
sclerocytes, which produce the mineral elements of the skeleton, called spicules125.   
 
Approximately 95% of sponge species belong to the subphylum Demospongiae 
(demosponges) and have skeletons consisting of silica and/or spongin fibres. The latter is a 
fibrous protein similar to keratin. Sponges live at all depths from shore level to the abyss. 
Sponges are permanently attached (sessile) and live in association with a number of 
organisms, which may be extra- and intracellular symbionts, commensals, parasites, or simply 
guests taking advantage of the shelter provided by the cavities of the sponge (crustaceans and 
nematodes). All demosponges contain extracellular bacteria, which sometimes can constitute 
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a biomass comparable or greater than that of the sponge itself. These symbiotic associations 
have considerable implications for attempts to establish the origin of metabolites extracted 
from sponges126. These compounds might be derived of the sponge itself, from one of the 
associated microorganisms or by some interaction between the sponge and the 
microorganism. In particular, associated bacteria are the origin of many substances involved 
in the defence of the sponge against predators, as in the case of the sesterterpenes produced by 
association between certain sponges and symbiotic zooxanthellae125. 
 
The great chemodiversity of metabolites from sponge species is equaled by the diversity of 
biological activity reported for the compounds; sponge metabolites have shown positive 
results in all the tests of biological activity which are in common use125. Table 1 lists some 
antimicrobial sponge metabolites isolated mainly in the last decade.  
 
The structures of some sponge metabolites are shown in Figure 4. The manzamines are a 
group of polyheterocyclic alkaloids containing a β-carboline. These compounds, which are 
isolated from the sponge Haliclona sp., exhibit a number of bioactivities including 
antibacterial, antifungal, cytotoxic and antimalarial activities125. Manzamine C is shown in 
Figure 4127. Niphatoxin A is a cytotoxic tripyridine alkaloid isolated from the sponge Niphates 
sp.128 Gelliusterol A-D are acetylenic sterols isolated from the sponge Gellius sp.129. The 







Table 1. Examples of antimicrobial natural products from sponge species isolated mainly in the last 
decade. 
Compound Region Species Chemistry 
Membranolides C-D Antarctica D.membranosa Diterpenes130 
Polymastamide A Norway P. boletiformis Steroid131, 132  
Discorhabdin R Antarctica Latrunculia sp. Alkaloid133  
Caminosides B-D Caribbean Sea C. sphaeroconia Glycolipids 134 
Spongosorites Korea Spongosorites sp. Alkaloid135 
Batzellaside A-C Madagascar Batzella sp Alkaloid136 
Dendridine A Japan Dictyodendrilla sp. Alkaloid137 
Halichonadin C Japan Halichondria sp Sequiterpene138 
Phenol Zanzibar D. herbacea Polyketide 139 
Spongistatin Indian Ocean H. erecta Polyketide140 
Latrunculins  Red Sea N. magnifica Polyketide141 
Nagelamide A Australia/Japan Agelas sp Alkaloid142 
Kalihinol Y and X Philippinnes Acanthella sp. Diterpene143 
Manoalide Palau Luffariella sp. Sesterterpene144 
Melophlin C Guam M. sarassinorum Polyketide145 
Ptilocaulis guanidine USA P. spiculifer Alkaloid146 
Cribrostatin 6 USA Cribrochalina sp. Alkaloid147 
Purpuramine L India P. purpurea Bromotyrosine alkaloid 148 
Germacrane Thailand Axinyssa sp. Sesquiterpene149 
Astroscleridae sterol/ Bahamas (from the 
deep sea) 
Astroscleridae sp Sterol sulfate150 
Dysidea sterols Australia D. arenaria Sterol151 
Massadine Japan S. aff. massa Alkaloid152 
Naamine G Indonesia L.  chagosensis Alkaloid153 
Utenospongin B Morocco H. communis Diterpene154 
Caminoside A Canada C. sphaeroconia Glycolipid155 
Zammamistatin Japan P. purpurea Bromotyrosine156 
Corticatic acids A-B Japan P. corticata Polyacetylenic acid157 
Swinehoeiamide A Papua New Guinea T. swinhoei Polyketide158 
Acetylenic acid Japanese Oceanapia sp Fatty acid159 
Dysidea ether Micronesia Dysidea sp. Bromodiiphenyl ether160 










Manzamine C                             Niphtaxin A                                                         Gelliusterol D 
 
Figure 4. Structures of the sponge metabolites manzamine C, niphtaxin A and gelliusterol D. 
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2.2 Antimicrobial natural products from ascidian species 
 
The class of ascidians (tunicates, phylum chordata) are sessile organisms, characterized by the 
presence of the notochord, a stiff rod which supports the body and is replaced in vertebrates 
by the spinal chord. Solitary ascidians are termed “simple ascidians” and colonial ascidians 
are described as “synascidians”. All ascidians are shaped like bags equipped with two 
siphons; an inhaling oral and exhaling excretion chamber. The ascidians live inside an 
external tunic (hence the name tunicates), which is rich in cellulose, and helps fix the animal 
to its substrate as well as providing shelter. These organisms are filter-feeders or suspension 
feeders; seawater charged with food particles enters through the oral siphon and circulates in 
the body through the gill. Some species filter several thousand times their own volume each 
day. Fixed ascidians can accommodate photosynthetic symbionts such as cyanobacteria. 
Ascidians are found in all the World’s seas and at all depths, but most species have been 
harvested within the upper 500 meters. Only 50 species have been found between 2000 and 
5000 metres165. 
 
Ascidians are one of the most widely studied marine organisms112. The majority of 
compounds isolated from ascidians are alkaloids111 and nitrogen-containing cyclic  
peptides165. The nitrogen-containing derivatives are often associated with aromatic nuclei 
among the alkaloids (indole, carbazole, pyridoacridine, isoquinoline) and with heteroaromatic 
nuclei among the cyclic peptides (thiazole, thiazoline, oxazole, oxazoline).  Most of these 
compounds possess antibiotic, anti-tumour, antiviral and immunosuppressive activities165. 
Most of the antimicrobial ascidian metabolites isolated in the last decade are listed in Table 2.  
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Some of the ascidian alkaloids have been found in other phyla of invertebrates suggesting that 
they might be of symbiotic bacterial origin. It is believed that most of the cytotoxic ascidian 
metabolites are involved in defense against predators and antifouling166, 167.  
 
Table 2. Antimicrobial natural products from tunicate species isolated in the last decade. 
Compound Region Species Chemistry 
Halocidin Korea H. aurantium Peptide168 
Plicatamide USA S. plicata Peptide169 
Eudistomin X Micronesia Eudistoma sp Alkaloid170 
(2S, 3R)-2-aminododecan-3-ol Brazil C. oblonga Polyketide171 
Dicunthaurin South Korea H. aurantium Peptide172 
Eudistomins Y6 Korea Eudistoma sp β-carboline173 
Tunichromes USA A. nigra Dihydrodpa alkaloids174 
Ciona peptide Germany C. intestinalis Peptide175 
Styela alkene Korea S. clava Sulfated alkene176 
Shishididemniols 1-2 Japan Family Didemnidae Lipids177, 178 
Lissoclibadins 4-7 Indonesia L. cf. badium Polysulfur alkaloids179 
 
 
2.2.1 Metabolites from Synoicum species 
 
Approximately 20 structures have been isolated from Synoicum species (Synoicum 
pulmonaria is shown in Figure 5). These have mainly been comprised of meroterpenes, 
macrolides and halogenated aromatic derivatives. Synoicum species consist only of colonial 
ascidians. The tunics of these species do not contain mineral spicules (skeletons) and several 
of the organisms are devoid of epibiosis165. However, microscopic analysis of Synoicum 
adareanum revealed a dense microbial community inside the tunicate180. 
 
Epiconicol (Figure 6), a cytotoxic meroterpene which was the first marine derivative of 
tetrahydrocannabinol, was isolated from an Asutralian ascidian,  Synoicum castellatum181. The  
highly cytotoxic nitrogen-containing macrolide, palmerolide A (Figure 6), was isolated from 
the Antarctic species Synoicum adareanum182. The rubrolides are a series of 15 halogenated 
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aromatic derivatives (without nitrogen) possessing strong antibacterial properties and 
moderate cytotoxicity165. Rubrolides have been isolated from a number of ascidians183, 184. 
Rubrolide O, isolated from a Synoicum n. sp. from New Zealand, also exhibited anti-
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                                                       Rubrolide O 
 
Figure 6. Structures of the Synoicum metabolites epiconicol, palmerolide A and rubrolide O. 
 
2.2.2 Metabolites from Dendrodoa species 
 
Ascidians of the genus Dendrodoa (Dendrodoa aggregata is shown in Figure 7) belong to the 
family Stylidae, which have yielded classical indole and pyridoacridine alkaloids and 
antibacterial peptides. Approximately a dozen structures have been isolated from Dendrodoa 
species. The common Dendrodoa grossularia (also known as baked bean ascidian and 
gooseberry seasquirt) is the most studied Dendrodoa species165.  
 
Several indolic alkaloids combining imidazolone have been isolated from Dendrodoa 
grossularia 186, 187. Alboinone, contains a rare oxadiazinone, the first of its kind from nature 
(Figure 8)188. No biological activity has been reported for these metabolites. Grossularines 1 
and 2 are two α-carboline alkaloids with moderate cytotoxic activity which have been isolated 
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from Dendrodoa grossularia (Figure 8)189. A cytotoxic, indolic derivative containing a 
thiadozole-1,2,4, named dendrodoine, has also been isolated from Dendrodoa grossularia 
























   Alboinone                                                Grossularine 1                                     Grossularine 2     
             
                                                         
                                                              Dendrodoine 
 
Figure 8. Structures of the Dendrodoa metabolites alboinone, grossularines 1 and 2, and dendrodoine. 
 
2.3 Antimicrobial natural products from coral species 
 
Soft corals, gorgonians or sea feathers, which belong to the phylum of Cnidaria (class 
Anthozoa), have been extensively studied and have produced the largest number of marine 
natural products besides sponge species85, 108, 110-112. These organisms are either solitary or 
colonial and are almost always fixed, with horny or calcareous skeletons. The class 
encompasses nearly 7 000 species, from which over 2 500 structures are known125. Most of 
the bioactive metabolites from coral species have exhibited cytotoxicity191. 
 
Approximately 90% of natural products from coral species have been terpenes, where the 
majority are diterpenes, followed by triterpenes and sesquiterpenes111, 125. This is reflected in 
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the list of antimicrobial compounds isolated from corals in the last decade (Table 3). Several 
hundred structures of prostanoids, a group of mainly cytotoxic terpenes which have been 
isolated from corals, appear to act as defense substances against predators125. Biosynthetic 
pathways for the production of prostanoids have been shown which appear to be specific to 
corals192-194. 
 
Table 3. Antimicrobial natural products from coral species isolated in the last decade. 
Compound Region Species Chemistry 
Xeniolide I  Kenya X. novaebrittanniae Terpene195  
Pseudopterosin X and Y Bahamas P. elisabethae Diterpene196 
A group of Lipids Indian Ocean S. grandilobata Polyketide197 
Erogorgiaenes Puerto Rico P. elisabethae Diterpene198 
Rumphellatin A Taiwan R. antipathies Norsesquiterpenoid199 
Caribenols 1-2 West Indies P. elisabethae Norditerpenes200 
Robustolides A-B Taiwan E. robusta Diterpene201 
C-secosteroids Argentina T. clavaria Steroids202 
 
Eighty natural products have been isolated from Alcyonium sp. consisting of sesqui- and 
diterpenes, preylquinones, sterols125 and nitric esters (these were the first known examples of 
natural nitrates)203. The moderately cytotoxic and antiviral steroid shown in Figure 9, was 
isolated from Alcyonium gracillimum along with six other steroids. 3-acetoxy-sterpurene (1) 
(Figure 9), a sesquiterpenoid with an unusual carbon skeleton was isolated from Alcyonium 
acaule204. No bioactivity was reported for this compound. 
 
                           
H
OAc  
                 A. gracillium sterol                                            3-acetoxy-sterpurene 
 
Figure 9. Structures of a sterol from Alcyonium gracillimum and 3-acetoxy-sterpurene isolated from 
Alcyonium acaule. 
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2.4 Antimicrobial natural products from bryozoan species 
 
Over 8000 species of bryozoans (also known as sea mats or sea mosses) have been described. 
Bryozoans are sessile filter-feeders and food is collected via a circle of tentacles (the 
lophophores). The basic body plan consists of a polyp, protected by a calcareous box termed a 
zooid and many zooids are grouped together to form the colony. These colonies host whole 
communities of microorganisms and small invertebrates within their structures205. It has  been 
shown that Endobugula sertula, a symbiont bacterium to the bryozoan Bugula neritina, is 
responsible for the production of the cytotoxic brysostatins, which cause the larvae to be 
unpalatable to predators. This is the first documentation of a symbiont providing defense  for 
























Figure 10. Structure of bryostatin 1 (R1 = OCOCOCH3, R2 = (CH)4(CH2)2CH3). 
 
Until 2006, only about 1% of reported marine natural products originate from bryozoan 
species (approximately 200 compounds)112 and only 32 species have so far been 
investigated.205. The majority of the bioactivities associated with bryozoans have been 
cytotoxic in nature; in fact, bryozoan metabolites have, along with those isolated from sponge 
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species, been some of the most potent cytotoxins isolated from marine species112. Only a few 
of the reported bryozoan metabolites have shown antimicrobial activity (Table 4). 
Chemically, the bryozoan metabolites have mainly been comprised of polyketides and 
alkaloids111, 165. There have been no previous reports of metabolites from Tegella species. 
 
There have been several discussions as to whether some bryozoan metabolites might be of 
microbial origin, as in the case of Flustramine E, isolated in Denmark from the bryozoan 
Flustra folicea208. The same compound has also been isolated from the Australian frog 
Pseudophyrne coriacea209. Different chemotypes of B. neritina were found at the same 
geographical location which harboured different strains of the symbiotic bacterium, E. 
sertula, known to produce the bryostatins210. 
  
Table 4. Antimicrobial natural products from bryozoan species isolated in the last 20 years. 
Compound Region Sp ies ec Chemistry 
Pterocellins C-F New Zealand P. vesiculosa Alkaloid211 
Amathaspiramides A, E/ New Zealand A.  wilsoni Dibrominated alkaloid212 
Alternatamides A-D USA A. alternata Peptide213 
Flustramine E Denmark F.foliacea Indolealkaloid214 
Biflustra quinine Australia B. perfragilis Isoquinoline quinone215 










3. Aims of the study 
 
The growing prevalence of infectious diseases and increasing resistance development by 
pathogenic bacteria and fungi poses a serious threat to the public health. Marine natural 
products have tremendous potential to yield novel antibiotics which can be effective in 
fighting multi-resistant pathogens. The aim of the present study was to investigate the 
presence of antimicrobial compounds in Arctic and sub-Arctic marine invertebrates and to 
determine the structures of active metabolites. Sponge and ascidian species in particular have 
yielded a number of bioactive compounds and were deemed to be promising targets for 
investigation.  
 
The main objectives of this study were to: 
 
• Screen extracts of a number of marine invertebrates for antimicrobial activity. 
• Purify and structurally elucidate active metabolites by mass spectrometric methods 










4. Summary of papers 
 
Paper I 
Margey Tadesse, Bjørn Gulliksen, Morten B. strøm, Olaf B. Styrvold, Tor Haug. 
Screening for antibacterial and antifungal activities from northern Norway. 
 
Benthic marine invertebrates collected from sub-Arctic regions of northern Norway, were 
found to be a promising source of novel bioactive compounds against human and fish 
pathogenic bacteria and fungi. Lyophilized material from seven species of ascidians, six 
sponges and one soft alcyonid coral were extracted with 60% acidified acetonitrile (ACN). 
After separation into an ACN-rich phase (ACN-extract) and an aqueous phase, and 
subsequent solid-phase extraction of the aqueous phase, fractions differing in polarity were 
obtained and screened for antibacterial and antifungal activities, along with the more 
lipophilic ACN-extracts. Antimicrobial activity was determined against two Gram-negative, 
two Grampositive bacteria, and two strains of fungi. Notably, all the invertebrate species in 
the study showed activity against all four strains of bacteria and the two strains of fungi. In 
general, the aqueous fractions displayed highest antimicrobial activity, and the most potent 
extracts were obtained from the colonial ascidian Synoicum pulmonaria which displayed 









Margey Tadesse, Veronika Tørfoss, Morten B. Strøm, Espen Hansen, Jeanette Hammer 
Andersen, Klara Stensvåg, Tor Haug.  
Isolation and biological activity of (E)-1-(4-hydroxystyryl)guanidine from the sub-Arctic 
ascidian, Dendrodoa aggregata. 
 
Bioguided-fractionation of an extract of the sub-Arctic ascidian, Dendrodoa aggregata, led to 
the isolation of the antibacterial (E)-1-(4-hydroxystyryl)guanidine (3-dihydroxy-tubastrine). 
The derivative, tubastrine, was also detected for the first time in Dendrodoa aggregata. The 
high content of 3-dihydroxy-tubastrine in Dendrodoa aggregata suggests that the compound 
could be a useful chemotaxonic marker for this species. 
 
Paper III 
Margey Tadesse, Morten B. Strøm, Johan Svenson, Marcel Jaspars, Bruce F. Milne, Veronika 
Tørfoss, Jeanette H. Andersen, Espen Hansen, Klara Stensvåg and Tor Haug. 
Synoxazolidinones A, B, and C; novel bioactive alkaloids from the ascidian Synoicum 
pulmonaria. 
 
Bioassay-guided fractionation of the sub-Arctic ascidian Synoicum pulmonaria collected off 
the Norwegian Coast, led to the isolation of a novel family of brominated guanidinium 
oxazolidinones named synoxazolidinones A-C. The backbone of the compounds contains a 4-
oxazolidinone ring rarely seen in natural products. The structure of the compounds was 
determined by spectroscopic methods. The synoxazolidinones exhibited antibacterial, 




Margey Tadesse, Jioji N. Tabudravu, Marcel Jaspars, Morten B. Strøm, Espen Hansen, 
Jeanette H. Andersen and Tor Haug. 
The antibacterial eusynstelamides B, D, E and F, from the Arctic bryozoan Tegella cf. 
spitzbergensis. 
 
The brominated tryptophan-derived metabolite eusynstyelamide B (1) and three new 
derivatives, eusynstyelamides D, E and F (2-4), were isolated from the Arctic bryozoan 
Tegella cf. spitzbergensis. The structures were elucidated by spectroscopic methods including 
1D and 2D NMR, and analysis of mass spectrometric data.  Eusynstyelamide B (1) has 
previously been isolated from the Australian ascidian, Eusynstyela latericius. In contrast to 
the former study, antibacterial activity is here reported for 1 against a number of bacterial 
strains at concentrations as low as 6.25 μg/ml. Likewise, antibacterial activity is reported for 
2-4. Eusynstyelamides 1-4 also exhibited antifungal activity against Candida albicans, and 
activity against the human melanoma cell line A-2058 was detected for 2 and 3. This is the 










5. General discussion 
5.1 Methodical considerations 
 
Norway possesses a long coastline with an abundance of biotas which have barely been 
investigated for bioactive compounds. At the commencement of the present work, seven 
species of ascidians, six sponge species and one soft alcyonid coral collected from the coast of 
northern Norway were extracted and investigated for their antimicrobial properties (Paper I). 
Common and abundant marine invertebrates, which would be easy to recollect if more 
material was needed, were chosen for the study. The organisms were typically collected by 
hand or trawl and deposited in large containers filled with circulating seawater, where they 
remained for a few days. The organisms were then frozen at -80 °C and lyophilized before 
extraction. Taxonomic identification was carried out by Prof. Bjørn Gulliksen (Norwegian 
College of Fisheries Science, University of Tromsø, Tromsø, Norway) and Ninel Panteleeva 
(Murmansk Marine Biological Institute KSC RAS, Murmansk, Russia). 
 
An extraction protocol using 60% acetonitrile (ACN) containing 0.1% triflouroacetic acid 
(TFA) as an extraction medium, was followed. This mixture has been proven effective at 
extracting both antibacterial peptides217-219 and other compounds such as steroids220 from a 
number of marine organisms. The extracts were incubated for 1-2 hours at -20 °C, resulting in 
two phases, an ACN-rich phase and a salt-rich water phase. The water phase was 
subsequently loaded on a solid phase extraction (SPE) cartridge and sub-fractionated with 
10%, 40% and 80% ACN containing 0.05% TFA. Active compounds were isolated from 
these fractions by reverse-phase high performance chromatography (RP-HPLC), as described 
in Papers II-IV. The ACN extracts were typically loaded on filter syringes prior to HPLC to 
discard insoluble material. The bryozoan species referred to in Paper IV was obtained through 
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our collaboration with Marbio (the Norwegian national screening platform) as a 
dichloromethane:methanol (DCM:MeOH) (1:1) extract, which was pre-purified by SPE prior 
to HPLC. 
 
An established antibacterial screening assay utilising a panel of human and fish pathogenic 
bacteria was used for testing218. The test bacteria consisted of two Gram positive bacteria, 
Staphylococcus aureus (ATTC 9144) and Corynebacerium glutamicum (ATTC 13032) (the 
latter being a particularly sensitive test bacterium)217, and three Gram negative bacteria, 
Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATTC 27853) and Listonella 
anguillarum (serotype O2, FT 1801, a fish pathogenic strain).  An antifungal assay using two 
strains of pathogenic fungi, Candida albicans (ATCC 10231) and Saccharomyces cerevisiae 
(a gift from Dr. Arne Tronsmo, The Norwegian University of Life Sciences, Ås, Norway) was 
also established. In paper I, an actively growing log phase culture of bacteria were diluted to 
an initial density of 5 x 103 cells per well and incubated with the test extracts for 72 hours. 
This was done in order to render the method sensitive to activity from low concentration 
compounds in the extracts. The test was conducted at 20 °C due to the inclusion of the marine 
bacterium L. anguillarum which does not grow at higher temperatures. Minimum inhibitory 
concentration (MIC) values of the pure compounds in papers II, III and IV were obtained 
using only human pathogenic bacteria with an initial bacterial concentration of 5 x 105 cells 
per well. The bacteria were incubated with the test compounds for 24 hours at 37 °C as a 
standard procedure.  
 
Activity screenings against S. aureus (ATCC 25923), Enterococcus faecalis (ATCC 29212) 
and methicillin-resistant S. aureus (MRSA) (ATCC 33591), as well as anti-cancer assays, 
were conducted through our collaboration with Marbio. Active compounds were characterized 
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by high resolution mass spectrometry (HR-MS) and nuclear magnetic resonance (NMR) 
spectroscopy, as described in Papers II-IV. 
 
5.2 Invertebrate species investigated in the present study 
 
Seven ascidian species, Synoicum pulmonaria, Ciona intestinalis, Dendrodoa aggregata, 
Styela rustica, Ascidia virginea, Corella parallelogramma and Halocynthia pyriformis, were 
extracted and investigated for antimicrobial activity. Six sponge species were also extracted 
and screened for activity; Geodia barretti, Haliclona sp. 1, Haliclona sp. 2, Haliclona rosea, 
Myxilla incrustans and Polymastia sp. Extracts of the soft alcyonid coral Alcyonium digitatum 
and the bryozoan Tegella cf. spitzbergensis, were also tested for activity. 
 
5.2.1 Antimicrobial activity in C. intestinalis  
 
The 40% and 80% SPE fractions of C. intestinalis displayed potent antimicrobial activity 
(Table 1 of Paper I.). HPLC and mass spectrometry were performed on both fractions, 
yielding two peptides with masses of 4.3 and 4.6 kDa in the 40% SPE fraction which co-
eluted on the HPLC. Identification of the peptides through database searches was not 
successful, possibly due to the fact that certain peptides often possess extensive post-
translational modifications including multiple monosulfide (lanthionine) bridges, disulfide-
bridges, amino acid derivatives and keto amide residues at the N-terminus40. Tryptination of 
the peptides followed by ESI-MS/MS analysis also proved unsuccessful. Re-purification of 
the peptides from the same extract was not possible, probably due to a degradation of the 
sample which can occur for a number of reasons. Peptides often prove to be problematic to 
purify. One example is the tunichrome peptides, which were extremely difficult to isolate due 
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to their great sensitivity to air, alkaline conditions and the solid phases usually used in 
chromatography221. Further work on the identification of the peptides was abandoned. 
 
Although C. intestinalis is a model organism, there are no reports so far of the isolation of 
antimicrobial peptides from this organism. However, a gene encoding for a putative 
antimicrobial peptide was recently identified in an expressed sequence tag (EST) database of 
C. intestinalis. A highly potent antimicrobial peptide was synthesized corresponding to the 
core cationic regions of the putative defense protein175. 
 
5.2.2 Antimicrobial activities in ascidian species 
 
Fractions of S. rustica and A. virginea displayed good antimicrobial activity (Paper I). HPLC 
and activity screening was performed both on the 40% and 80% SPE fractions without 
resulting in the isolation of active metabolites. Only minor peaks were observed by HPLC 
signifying that the fractions contained compounds present at minute concentrations. 
Antimicrobial activity was not found in any of these HPLC fractions indicating that the initial 
activity might be due to a possible synergetic effect which is lost upon separation of the 
components40, 66. The fact that active substances have previously been isolated from these 
species could signify that the organisms collected for this study did not produce these 
metabolites due to environmental, seasonal or chemotype variations.  It is also possible that 
the separation method employed in the present investigation was not amenable to the isolation 
of the metabolites potentially present in these organisms.  
 
A very limited amount of sample of C. parallelogramma was available for extraction and it 
was not deemed feasible to extract enough material for structural elucidation. Fractions of H. 
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pyriformis possessed poor activity in our assays, thus no attempt at purification of compounds 
from the organism was carried out. 
 
5.2.3 Antimicrobial activities in sponge and coral species  
 
Bio-guided fractionation of the sponge G. Baretti, led to the isolation of the known, 
brominated antifouling compound barettin222, 223 (Figure 2). The compound was detected in 
the 40% SPE fraction and identified by HR-MS which showed the isotope pattern and mass 
(m/z 419 [M + H]+). The HPLC fraction containing the compound showed antibacterial 
activity against the Gram-negative bacterium P. aeruginosa and the Gram-postive bacterium S. 
aureus. However, no MIC studies were carried out and further isolation for NMR studies was 
not pursued due to dereplication. 
  
HPLC and activity screening in the present work did not result in the isolation of 
antimicrobial metabolites from the sponge species Haliclona sp. 2, H. rosea, M. incrustans, 
Polymastia sp. or the soft coral A. digitatum. Attempts at isolation of compounds from 
Haliclona sp 1 was not carried out due to the poor activity of the SPE fractions. The 
taxonomy of Haliclona sp 2 was later corrected to Mycale sp. and a Master project was 
carried out at our department attempting to isolate active metabolites from this species. 
However, it did not lead to the identification of new compounds224. 
  
 5.2.4 3-dehydroxy-tubastrine and tubastrine from the ascidian D. aggregata 
 
Bio-guided fractionation of the ascidian D. aggregata resulted in the isolation and 
characterization of the antimicrobial hydroxystyrylguanidine alkaloids, 3-dehydroxy-
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tubastrine and tubastrine (Figure 11), as described in Paper II.  The structure of 3-dehydroxy-
tubastrine was elucidated by high resolution mass spectrometry and NMR techniques, while 
tubastrine was characterized by high resolution mass spectrometry. 3-dehydroxy-tubastrine, 
which had previously been isolated from the Australian sponge Spongosorites sp., displayed 
antibacterial activity against S. areus, C. glutamicum and MRSA at an MIC of 100 μg/ml. 
Antibacterial activity against S. aureus and C. glutamicum were observed for tubastine but 
MIC-values were not determined. This is the first report of active metabolites from D. 
aggregata. Due to its abundance in the organism, 3-dehydroxy-tubastrine can serve as a 
chemotaxonomic marker for the species. However, as noted in Paper II, there is a good 
probability of biogenesis by symbiotic microorganisms which should be considered. 
 
Tubastrine has previously been isolated from a number of organisms and has exhibited 
various activities including antiviral properties, kinase inhibition, as well as functioning as a 
defense for the organisms against microbes and larvae (Paper II).  A series of dimers of 
tubastrine, exhibiting anti-inflammatory activity, have been isolated from the ascidian 
Aplidium orthium225. One of these, orthidine E is shown in figure 11. 
 













     
            3-dehydroxy-tubastrine                               Tubastrine                                 Orthidine E                                         
 
Figure 11. Structures of 3-dehydroxy-tubastrine, tubastrine and orthidine E.                                                          
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5.2.5 Synoxazolidinones A, B, and C, novel oxazolidinones from S. pulmonaria 
 
HPLC was performed on the ACN extract of S. pulmonaria, which was the most active 
fraction in the initial antimicrobial screening (Paper I). This extract was found to mainly 
consist of three distinct peaks in approximately a 1:7:2 ratio. The first peak yielded a 
compound with m/z of 460 (C15H18Br2N4O3), the second and most abundant peak showed a 
m/z of 494 (C15H17Br2ClN4O3) and a m/z of 492 (C15H15Br2ClN4O3) was observed for the last 
compound. Tandem mass spectrometric analysis along with 1 and 2D NMR experiments 
discussed in Paper III, led to the structural elucidation of these compounds which were named 
synoxazolidinones A, B, and C (Figure 12). Synoxazolidinones A, B, and C contain a unique 
4-oxazolidinone core. The absolute stereochemistry of the compounds was deduced by 
computational experiments, which are described in detail in the supporting information to 
Paper III. This needs to be confirmed by future synthesis of the synoxazolidinones. 
                         
Synoxazolidinone A (6Z, 10S, 11S)                          Synoxazolidinone B (6Z, 10S, 11S) 
                                                      
                                                             Synoxazolidinone C (6Z, 10S)        
Figure 12. Structures of the novel 4-oxazolidinones, synoxazolidinones A, B, and C. 
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The synoxazolidinones represent a novel scaffold incorporating a rare 4-oxazolidinone core 
that adds to the chemodiversity of reported natural products. The compounds exhibited 
various antimicrobial and anti-cancer activities, some with MIC-values as low as 6.25 μg/ml 
(Paper III). Isolation of bioactive compounds has previously not been reported for S. 
pulmonaria species. Notably, the synoxazolidinones were not present in S. pulmonaria 
species collected off the coast of Spitsbergen (data not shown), a different location than the 
north Norwegian coast, where the organisms originally extracted were obtained. This is yet an 
example of environmental and/or seasonal variations in the chemical content of organisms.  
 
The 1HNMR and 13CNMR spectra of the synoxazolidinones, contained relatively few proton 
and carbon signals. However, adequate gCOSY and gHMBC correlations were observed 
enabling determination of the structure of the compounds (Paper III). Tandem mass 
spectrometric fragments of synoxazolidinone A (shown in the supporting information to Paper 
III) also yielded a stepwise confirmation of the proposed structure of synoxazolidinone A. 
 
The configuration of the double bond between C-6 and C-7 was determined as Z due to the 
low coupling constants between H-6 and C-8 (3J(C,H) <3 Hz). The assignment is based on the 
literature value for the 3J(C,H) coupling constant for a cis-double bond (7.6 Hz), which is 
lower than the 3J(C,H) (14.1 Hz) coupling constant for a trans-double bond (Paper III). An 
EXSIDE experiment, which directly measures nJ(C,H) coupling constants by analysing 
correlations in the 13C dimension, was used to measure the coupling constants (supporting 
information to paper III). Calculations based on CD experiments also supported a Z-
configuration at this position (Paper III).  
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The structures of the synoxazolidinones suggest biogensis from tyrosine and 
arginine/agmatine: The guanidine group of arginine is conserved in the synoxazolidinones. A 
suggested biosynthetic route for the formation of the synoxazolidinones is presented in Paper 
III.  
 
The first member of the oxazolidinone class of antibacterials was furazolidone, which was 
synthesized in the 1950’s (Figure 13). DuPont Pharmaceuticals developed the oxazolidinone 
lead compounds DuP 105 and D 721 in the late 1980’s but these were subsequently 
abandoned due to their toxic nature. Linzolid (Zyvox TM) is the most recent antibacterial 
oxazolidinone drug to be marketed (Figure 13). Eperzolid, an oxazolidinone drug similar to 
linzolid, was a back-up candidate which could not be developed due to large dosages and 
bone-marrow toxicity226. Apart from the marine oxazolidinones discussed previously, two 
oxazolidinones have been isolated from terrestrial sources; the cytokine modulator 
cytoxazone, isolated from a soil Streptomyces strain227, and the mildly antimicrobial 
streptazoline, which was isolated from Streptomyces viridochromogenes228 (Figure 13). 
 
                     
                                  Furazolidone                                                              Linezolid 











                              Cytoxazone                                                                     Streptazoline 
Figure 13. The oxazolidinones furazolidone, linezolid, cytoxazone and streptazoline. 
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Numerous derivatives of linezolid have been synthesized. Srivastava et al.226 discuss the 
structure-activity relationships governing oxazolidinone development. An electron rich atom 
such as the nitrogen of the morpholine ring of linezolid, was found to improve the safety 
profile of the drug. The fluorine on the phenyl group was found to improve antibacterial 
activity. The N-aryl group at position N3 and an S-configuration at C5 of the oxazolidinone-
ring, were requirements for antibacterial activity. The synoxazolidinones also contain an 
electron-rich methoxy group in the 4 position in addition to two bromines in the 3 and 5 
positions of the phenyl ring (a di-flouro derivative of linezolid was found to be promising). 
Synoxazolidinones contain a unique 4-oxazolidinone moiety, providing an entirely novel 
scaffold for structure-activity relationship studies. These studies are currently being carried 
out in order to optimalise the structures of the synoxazolidinones for clinical use. 
 
5.2.6 The antibacterial eusynstyelamides B, D, E and F, from T. spitzbergensis 
 
An investigation into the chemistry of the Arctic bryozoan Tegella cf. spitzbergensis, resulted 
in the isolation and structural identification of the known dibrominated tryptophan-derived, 
guanidine dimer, eusynstyelamide B229 (Figure 14). Three new derivatives, eusynstyelamides 
D, E and F, were also isolated and characterized (Figure 14). Eusynstyelamide B has 
previously been isolated from the Australian ascidian Eusynstyela latericius229. The structures 
of the eusynstyelamides were elucidated by mass spectrometric and, 1D and 2D NMR 
techniques. The carbon shift values were obtained through gHSQC and gHMBC experiments 
(Paper IV). Eusynstyelamide B was identified by comparison of the mass, isotope pattern and 
NMR shift values of the compound with those reported by Tapiolas et al229. Eusynstyelamides 
D, E and F, were characterized by their mass values, isotope pattern and comparison of their 
1HNMR and 13CNMR shift values with those of eusynstyelamide B. Determination of the 
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relative configuration of eusynstyelamide B based on NOE signals, is discussed in paper IV. 
The same relative configuration as eusynstyelamide B is proposed for eusynstyelamides D, E 




















































































Eusynstyelamide E (9R*, 25S*, 26R*) Eusynstyelamide F (9R*, 25S*, 26R*) 
 
Figure 14. Structures of the antibacterial eusynstyelamides B, D, E and F from T. spitzbergensis. 
 
All four compounds exhibited antibacterial activity. There was no apparent relationship 
between the loss of guanidine-groups at various locations in eusynstyelamides D, E and F, 
and their antibacterial properties, as all four compounds exhibited similar antibacterial 
activities (Paper IV). This is the first report of bioactive metabolites from a Tegella species.  
The fact that eusynstyelamide B was found in different geographical zones points to 
biosynthsis by symbiotic microorganisms.  
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Tapiolas et al.229 attempted to determine the absolute configuration of eusynstyelamide B 
without success. In the future, an attempt could be made to solve the absolute configuration of 
the eusynstyelamides either through computational means or X-ray crystallography. 
Structure-activity relationship studies could also be carried out to identify structural elements 
essential for the antibacterial activity of eusynstyelamides B, D, E and F, and thereby 




















5.3 Main conclusions 
 
• Arctic and sub-Arctic marine invertebrates were found to be promising sources of 
novel antimicrobial metabolites. 
 
• The antibacterial compounds 3-dihydroxy-tubastrine and tubastrine, have been 
isolated from the ascidian Dendrodoa aggregata. This is the first report on the 
isolation of bioactive metabolites from this species. 
 
• The antimicrobial and anticancer compounds, synoxazolidinones A, B, and C, have 
been isolated from the ascidian Synoicum  pulmonaria and provide novel scaffolds for 
structure-activity relationship studies. This is the first report of bioactive metabolites 
from S. pulmonaria. 
 
• The antimicrobial eusynstyelamide B and three new derivatives, eusynstyelamides D, 
E and F, have been isolated from the bryozoan Tegella cf. spitzbergensis. This is the 
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